.png)
Introduction: The Urgency and Promise of Drug Repurposing in Pancreatic Cancer Therapy
Pancreatic cancer remains one of the deadliest cancers, with a five-year survival rate lingering near 10-13% in the United States. It ranks low in incidence but is notably high in mortality, underscoring the aggressive nature of the disease and the limitations of current treatments. Challenges include late diagnosis, often when tumors are advanced or metastatic, and resistance to traditional therapies like surgery, chemotherapy, and radiation.
Drug repurposing offers a promising avenue to accelerate the development of effective pancreatic cancer treatments. This approach involves identifying new anticancer uses for existing FDA-approved medications originally developed for other conditions. Repurposed drugs benefit from established safety profiles and known mechanisms of action, potentially reducing the time and cost of bringing new therapies to patients.
Advancing beyond standard treatments is critical, as improvements in survival have been modest despite decades of research. With pancreatic tumors exhibiting complex genetic mutations and a suppressive tumor microenvironment, innovative strategies are necessary. Drug repurposing, combined with precision medicine and immunotherapy, is paving the way for more personalized and effective interventions.
Hirschfeld Oncology exemplifies the integration of cutting-edge innovation with proven therapies, leveraging multidisciplinary expertise to expand available options for pancreatic cancer patients. By incorporating drug repurposing insights alongside surgery, chemotherapy, radiation, and emerging targeted agents, this approach holds significant promise for improving outcomes in this challenging disease.
Key Facts on Pancreatic Cancer Treatment Innovations
- Auranofin targets oxidative stress pathways by inhibiting TrxR1 and HIF1α, promoting ROS accumulation and inducing apoptosis.
- Reactive oxygen species (ROS) accumulation under nutrient deprivation leads to oxidative stress and selective cancer cell death.
- Combining auranofin with human cyst(e)inase increases mitochondrial ROS and inhibits autophagy, suppressing tumor growth in preclinical models.
- Disulfiram, originally for alcoholism, now repurposed due to its ability to inhibit proteasome and target cancer stem cells.
- Disulfiram induces autophagy-dependent apoptosis and inhibits NF-kB signaling, helping to deplete resistant cancer stem cells.
- Metformin activates AMPK, inhibits mTOR, reduces insulin/IGF-1 signaling, and modulates immune responses, which may slow pancreatic cancer progression.
- Epidemiological data suggest that metformin use correlates with improved survival in pancreatic cancer patients, supporting its repurposing.
- Haloperidol and penfluridol induce ER stress, triggering autophagy and apoptosis, thereby reducing tumor growth and metastasis.
- Nelfinavir inhibits Akt signaling and acts as a radiosensitizer, enhancing radiotherapy efficacy in pancreatic cancer.
- Hirschfeld Oncology is led by Dr. Azriel Hirschfeld, employing a multidisciplinary, personalized approach combining innovative therapies with compassionate patient care.
1. Auranofin: Targeting Oxidative Stress to Inhibit Pancreatic Tumor Progression
How does auranofin and human cyst(e)inase combination inhibit pancreatic cancer progression?
Auranofin for pancreatic cancer, originally approved for rheumatoid arthritis, has shown promising anti-cancer effects in pancreatic cancer by targeting oxidative stress pathways. The drug inhibits thioredoxin reductase 1 (TrxR1) and hypoxia-inducible factor 1-alpha (HIF1α). These proteins are crucial for maintaining redox balance and cellular adaptation to low oxygen, respectively, which cancer cells depend on for survival and metastasis.
What role does reactive oxygen species (ROS) play in auranofin's action?
Auranofin cytotoxicity under nutrient deprivation promotes the accumulation of reactive oxygen species (ROS) particularly under nutrient-deprived conditions typical of the pancreatic tumor microenvironment. The elevated ROS leads to oxidative stress, triggering apoptosis (programmed cell death) in pancreatic cancer cells. This oxidative mechanism preferentially kills cancer cells while sparing normal cells, providing a therapeutic window.
How does combining auranofin with human cyst(e)inase enhance treatment efficacy?
When auranofin is combined with human cyst(e)inase, an enzyme that depletes extracellular cysteine and cystine, there is a further increase in mitochondrial ROS production and inhibition of autophagy, a survival mechanism for cancer cells. This synergy amplifies oxidative stress, resulting in stronger suppression of pancreatic tumor growth in preclinical models.
What evidence supports auranofin's effectiveness in pancreatic cancer?
Preclinical studies using pancreatic cancer models have demonstrated that auranofin alone reduces tumor viability by inducing apoptosis and suppresses metastasis. Moreover, the combination with cyst(e)inase significantly diminishes tumor growth, indicating potential clinical benefit. These findings highlight auranofin's promise for repurposing as part of combination therapies for pancreatic cancer treatment.
2. Disulfiram: Exploiting Proteasome Inhibition and Cancer Stem Cell Targeting
What was Disulfiram originally used for and why is it repurposed for pancreatic cancer?
Disulfiram was originally approved for the treatment of alcoholism, helping to discourage alcohol consumption by inducing unpleasant effects when alcohol is ingested. Recent research has uncovered its potential for repurposing as a cancer therapeutic agent, particularly in Disulfiram anticancer mechanisms. This repurposing is motivated by its ability to interfere with molecular pathways critical to cancer cell survival.
How does Disulfiram work against pancreatic cancer cells?
Disulfiram acts by inhibiting the proteasome, an essential protein complex responsible for degrading damaged or unneeded proteins in cells. This inhibition interferes with the proteostasis of cancer cells. Additionally, Disulfiram suppresses the NF-kB signaling pathway, which is commonly activated in pancreatic tumors and promotes cancer cell proliferation, survival, and resistance to chemotherapies.
What cellular processes does Disulfiram promote to induce cancer cell death?
The drug promotes autophagy-dependent apoptosis, a process where cellular components are degraded within lysosomes leading to programmed cell death. Crucially, Disulfiram targets and depletes cancer stem cells, which are thought to drive tumor recurrence and metastasis due to their drug resistance and ability to self-renew. This characteristic makes Disulfiram especially promising for treating pancreatic cancer, known for its aggressiveness and high relapse rates.
Are there clinical trials evaluating Disulfiram's efficacy in pancreatic cancer treatment?
Yes, clinical trials are currently underway to evaluate the safety and effectiveness of Disulfiram in pancreatic cancer patients. These studies aim to determine whether Disulfiram can enhance survival rates, potentially in combination with standard chemotherapy regimens, by targeting mechanisms unique to pancreatic tumor biology. This research reflects growing interest in repurposed drugs that can expedite the availability of new treatment options without the delays associated with developing entirely novel agents.
3. Metformin: An Anti-Diabetic Agent Offering Anticancer Effects in Pancreatic Disease
How does metformin activate AMPK and inhibit mTOR pathways?
Metformin, widely used as an anti-diabetic medication, exerts notable anticancer effects by activating AMP-activated protein kinase (AMPK). Activation of AMPK serves as a cellular energy sensor that inhibits the mammalian target of rapamycin (mTOR) pathway, a critical regulator of cell growth and proliferation often dysregulated in cancers including pancreatic cancer. By downregulating mTOR activity, metformin impairs pancreatic tumor cell growth and survival, effectively slowing tumor progression (Metformin activating AMPK and inhibiting mTOR).
What is the impact of metformin on insulin and IGF-1 signaling related to tumor growth?
Pancreatic cancer growth is frequently influenced by high insulin and insulin-like growth factor 1 (IGF-1) signaling, which can promote tumorigenesis. Metformin lowers circulating insulin levels and reduces insulin/IGF-1 signaling pathways. This reduction diminishes pro-growth signals that would otherwise facilitate pancreatic tumor proliferation, thereby potentially suppressing cancer development and progression (Metformin activating AMPK and inhibiting mTOR.
Does metformin modulate immune responses in pancreatic cancer?
Emerging research suggests that metformin may modulate the immune environment within pancreatic tumors. By influencing pathways linked to inflammation and immune system activity, metformin could improve the tumor microenvironment, making it more amenable to immune-mediated destruction of cancer cells. This immune modulation is an avenue of active investigation, as it aligns with efforts to enhance pancreatic cancer immunotherapy (Metformin activating AMPK and inhibiting mTOR; Immunotherapy for pancreatic cancer clinical trials).
What do epidemiological studies indicate about metformin’s effect on survival in pancreatic cancer?
Epidemiological studies have shown promising associations between metformin use and improved survival outcomes in pancreatic cancer patients. Observational data suggest that diabetic patients undergoing metformin treatment may experience prolonged survival compared to those not on metformin. Such findings support ongoing clinical interest in repurposing metformin as part of pancreatic cancer therapeutic regimens to boost patient prognosis and quality of life (Metformin activating AMPK and inhibiting mTOR; Repurpose existing therapeutics for cancer treatment).
In summary, metformin’s multiple mechanisms—activating AMPK, inhibiting mTOR pathways, reducing insulin/IGF-1 signaling, and modulating immune responses—collectively present it as a valuable adjunct therapy in pancreatic cancer. These biochemical effects, backed by encouraging epidemiological evidence, highlight the potential of metformin repurposing strategies to improve outcomes for this challenging disease.
4. Haloperidol and Penfluridol: Antipsychotic Drugs Inducing ER Stress to Suppress Tumor Growth
How does Haloperidol blocking DRD2 in pancreatic cancer work to affect pancreatic cancer cells?
Haloperidol, traditionally used as an antipsychotic medication, acts by blocking the dopamine receptor D2 (DRD2). This blockade triggers endoplasmic reticulum (ER) stress within pancreatic cancer cells, a cellular condition that disrupts normal protein folding and function. The induced ER stress leads to apoptosis, a programmed cell death mechanism that helps reduce cancer cell survival. Preclinical studies have shown that haloperidol's ability to induce ER stress contributes to suppressed tumor growth and decreased metastasis in pancreatic cancer models.
What role does Penfluridol inducing ER stress and apoptosis play in pancreatic cancer treatment?
Penfluridol, another antipsychotic drug, also induces ER stress in pancreatic cancer cells, but its mechanism extends further by activating cellular autophagy and apoptosis pathways. Autophagy initially acts as a survival mechanism but, when sustained excessively, contributes to cancer cell death. By inducing both autophagy and apoptosis through ER stress, penfluridol effectively suppresses tumor growth.
What have preclinical studies revealed about their effectiveness?
Experimental pancreatic cancer models demonstrated that both haloperidol and penfluridol significantly reduce tumor size and metastasis. Penfluridol was particularly effective, halving tumor growth in these models. These findings highlight their potential as repurposed drugs in pancreatic cancer therapy, targeting cancer cells through stress pathways uncommon in standard treatments.
How does penfluridol interact with existing chemotherapy?
Penfluridol has shown synergistic effects when combined with gemcitabine, a standard chemotherapy drug for pancreatic cancer. The combination enhances the therapeutic efficacy beyond the use of gemcitabine alone, offering a promising approach to improving treatment outcomes. This synergism supports ongoing research into integrating antipsychotic agents into multi-drug regimens for pancreatic cancer.
Together, haloperidol and penfluridol reveal how drugs outside traditional chemotherapy can disrupt cancer cell homeostasis through ER stress, presenting innovative pancreatic cancer treatments and innovative avenues to combat pancreatic cancer's aggressive behavior.
5. Itraconazole: Antifungal Agent with Potential to Inhibit Cancer Cell Growth and EMT
How Does Itraconazole Affect Pancreatic Cancer Cells?
Itraconazole, traditionally known as an antifungal medication, has shown promising effects against pancreatic cancer cells. Its anticancer action primarily involves inducing apoptosis, the process of programmed cell death, which is crucial for eliminating malignant cells. Additionally, Itraconazole suppressing EMT in pancreatic cancer suppresses epithelial-mesenchymal transition (EMT) in pancreatic cancer, a process by which cancer cells acquire increased mobility and invasiveness, contributing to metastasis. By interfering with EMT, itraconazole may limit the spread of pancreatic tumors.
What Does Clinical Data Reveal About Itraconazole’s Benefits?
Retrospective clinical studies indicate that pancreatic cancer patients who received itraconazole might experience improved survival outcomes compared to those who did not. Although these findings are preliminary, they suggest that itraconazole's repurposing as an oncology agent could offer therapeutic advantages.
Why Is Drug Repurposing of Itraconazole Significant?
Repurposing itraconazole from an antifungal to a cancer treatment represents a valuable strategy in drug repurposing strategy for pancreatic cancer therapy. Since itraconazole is already FDA-approved for fungal infections, its safety profile and pharmacokinetics are well understood. This knowledge can accelerate clinical trials and reduce the development costs and time typically associated with new drug candidates.
Are There Broader Investigations Into Itraconazole’s Anticancer Effects?
Ongoing research is exploring itraconazole’s potential beyond pancreatic cancer, assessing its effects in various tumor types. The focus lies on understanding its molecular targets, optimizing dosage for anticancer efficacy, and evaluating combination therapies with standard chemotherapeutic agents to enhance treatment responses.
This multifaceted approach exemplifies how itraconazole could transition from its original antifungal use to becoming an innovative pancreatic cancer treatment.
6. Nelfinavir: An HIV Protease Inhibitor Enhancing Radiosensitivity in Pancreatic Cancer
How Does Nelfinavir Inhibiting Akt and Enhancing Radiosensitivity to Impact Pancreatic Cancer?
Nelfinavir, originally developed as an HIV protease inhibitor, has been discovered to inhibit the Akt signaling pathway, which is commonly overactive in pancreatic cancer cells. Akt plays a crucial role in promoting tumor cell survival, proliferation, and resistance to therapies. By blocking Akt, nelfinavir disrupts these cancer-promoting signals, thereby sensitizing pancreatic tumor cells to treatment effects.
What Are Nelfinavir’s Effects on Radiation Therapy for Pancreatic Cancer?
Nelfinavir acts as a radiosensitizer, meaning it enhances the sensitivity of pancreatic cancer cells to radiation therapy. This radiosensitizing effect improves the overall efficacy of radiation treatment by increasing tumor cell death when combined with radiation. Studies suggest that when nelfinavir is administered along with radiation, there can be more effective tumor control compared to radiation alone.
What Clinical Trial Evidence Supports Nelfinavir’s Use in Pancreatic Cancer?
Clinical trials have demonstrated that nelfinavir is generally well tolerated by pancreatic cancer patients during combined chemoradiation therapy. Patients have experienced manageable side effects, and the combination has shown encouraging safety profiles. Though these trials confirm the feasibility of adding nelfinavir to standard radiation regimens, larger studies are needed to validate improvements in survival outcomes.
What Challenges Limit the Widespread Use of Nelfinavir in Pancreatic Cancer?
A significant challenge to using nelfinavir broadly in pancreatic cancer therapy is supply and availability concerns that have occasionally affected access to the drug. Despite its promising radiosensitizing properties, these logistical issues pose barriers to incorporating nelfinavir into routine clinical practice. Ongoing efforts focus on addressing these supply problems to enable more widespread clinical use.
| Aspect | Details | Significance |
|---|---|---|
| Mechanism | Inhibits Akt signaling pathway | Reduces tumor cell survival and therapy resistance |
| Radiosensitizing Effect | Enhances radiation therapy efficacy | Improves tumor control |
| Clinical Trial Profile | Safe and well tolerated in chemoradiation trials | Supports combined treatment potential |
| Limiting Factor | Drug supply and availability issues | Challenges broad clinical implementation |
Nelfinavir’s repurposing as a radiosensitizer for pancreatic cancer exemplifies innovative pancreatic cancer treatments to improve treatment efficacy. Its inhibition of Akt and ability to boost radiation effects offer hope for better management strategies in this difficult-to-treat disease, pending resolution of supply hurdles.
Leadership and Compassionate Multidisciplinary Care at Hirschfeld Oncology
Who leads the pancreatic cancer treatment program at Hirschfeld Oncology?
The pancreatic cancer treatment program at Hirschfeld Oncology is led by Dr. Azriel Hirschfeld, a highly respected specialist renowned for his dedication to advancing cancer care. Dr. Hirschfeld integrates innovative pancreatic cancer treatments with standard treatments, focusing on personalized care plans that reflect the latest scientific research and clinical experience. This leadership ensures that patients receive tailored and advanced treatment options, embodying a commitment to both cutting-edge medicine and compassionate care.
How does Hirschfeld Oncology's medical team collaborate to design treatment plans for pancreatic cancer patients?
Hirschfeld Oncology employs a multidisciplinary team approach, bringing together physicians, nurses, and various medical staff. Under Dr. Hirschfeld’s guidance, this team thoroughly reviews each patient's medical history, genetic information, and individual needs to create customized treatment plans. Regular collaborative meetings promote open communication and coordinated care strategies, blending established therapies with novel innovations. This teamwork enhances treatment effectiveness while providing patients and their families with thorough support and clear information throughout the care process.
What innovative strategies are being used in pancreatic cancer treatment at Hirschfeld Oncology?
The clinic integrates state-of-the-art treatments, including precision medicine driven by genetic and molecular profiling. Hirschfeld Oncology actively participates in clinical trials testing cutting-edge therapies such as direct liver-delivered chemotherapy to prevent metastasis and personalized mRNA vaccines designed to provoke strong immune responses against cancer cells. Collaborations with national institutes to explore immunotherapies, including advanced T cell therapies, showcase their commitment to improving cure and recurrence rates. Perioperative clinical trials targeting specific tumor genetics further demonstrate their innovative care ethos.
What role does compassion play in pancreatic cancer treatment at Hirschfeld Oncology?
Compassion is foundational to every aspect of care at Hirschfeld Oncology. The medical team prioritizes emotional support and empathy, recognizing the unique challenges each patient faces. This compassionate approach fosters trust, alleviates anxiety, and encourages open communication, empowering patients to actively participate in their treatment decisions. By honoring the person beyond their diagnosis, Hirschfeld Oncology enhances patients' overall well-being and resilience, enriching the treatment experience at every stage.
This combined leadership, innovative teamwork, and compassionate care at Hirschfeld Oncology exemplify a patient-centered approach designed to improve outcomes and provide hope for those affected by pancreatic cancer.
Conclusion: Harnessing Repurposed Drugs to Transform Pancreatic Cancer Treatment
Promising Repurposed Drugs and Their Mechanisms
Several repurposed drugs show notable potential in pancreatic cancer treatment due to their unique mechanisms. Auranofin, initially for rheumatoid arthritis, promotes cancer cell apoptosis by inhibiting TrxR1 and HIF1α and inducing reactive oxygen species (ROS). Haloperidol triggers ER stress, reducing tumor growth and metastasis by blocking dopamine receptor DRD2. Disulfiram, used for alcoholism, depletes cancer stem cells and induces autophagy-dependent apoptosis. Metformin, primarily a diabetes drug, activates AMPK and inhibits signaling pathways like mTOR to suppress tumor progression. Losartan, an antihypertensive, improves chemotherapy delivery by reducing fibrosis and collagen in tumors. Lastly, Nelfinavir, an HIV protease inhibitor, increases radiosensitivity and inhibits key survival pathways in cancer cells.
Impact on Survival and Quality of Life
Drug repurposing offers a transformative opportunity to extend survival and enhance quality of life for pancreatic cancer patients, especially given the disease’s current high mortality and limited treatment options. With established safety profiles, repurposed drugs can reduce development time and cost, accelerating availability. Their diverse mechanisms target resistant cancer pathways, cancer stem cells, and tumor microenvironments, thereby complementing existing therapies and potentially improving treatment responses.
Role of Multidisciplinary and Compassionate Care
As underscored by exemplary centers like Hirschfeld Oncology, integrating repurposed drugs into comprehensive multidisciplinary care—including surgery, chemotherapy, radiation, and supportive services—ensures the best patient outcomes. Compassionate care that addresses physical, emotional, and social needs remains essential while novel therapies emerge.
Future Directions
Ongoing research continues to illuminate molecular targets and synergistic drug combinations, many tested through innovative clinical trials and assisted by artificial intelligence. The evolution of targeted therapies, immunotherapies, and advanced delivery systems promises to improve prognosis. Continued integration of repurposed drugs with cutting-edge innovations will be central to transforming pancreatic cancer from a lethal diagnosis to a more manageable disease.
.png)
.png)
